FIG 1. Patient derived induced pluripotent stem cells (iPSc)- reprogrammed from extracted FUE.

HAIROID™️  ADVOCATES STRICTLY AGAINST THE USE OF ANIMALS IN ANY OF IT‘S TECHNOLOGIES  IN ACCORDANCE WITH THE DIRECTIVE OF THE EUROPEAN UNION NO.: 1223/2009 [ON COSMETICS] . THEREFORE HAIROID™️ STRICTLY REJECTS ANY ANIMAL TESTING FOR COSMETIC AND MEDICAL HAIR-RESEARCH.

“Initially we had no intention to replicate hair, because we were hesitant to participate in an industry facing a lot of criticism from all scientific fields for raising patient expectations and then not being able to deliver satisfactory results based on factual scientific developments. Furthermore we believe that it’s imperative to develop causal and symptomatic therapies in the field of Alopecia and process them in our own transplantation centers with only the most accomplished surgeons in the field.

Various conducted stainings of our prototypes confirmed that HAIROID™️ IP protected and produced a fully formed -entirely- human hairfollicle with the potential for being transplanted into the human scalp, bringing total disruption to the hairtransplant and haircosmetics industry. However, given the world wide  prevalence of ALOPECIA we see it as our mission to support scientific colleagues with our invention as it‘s evident that the entire field can’t be covered by one single company“.

Up today there is a variety of methods for tissue fabrication for multiple tissue types (Patentapplication US20170130192A1; Patent application US6096347A; Patent JP5893786B2; Patentapplication WO2017077985A1).

Evidently, none of them successfully developed autologous and hypoimmunogenic in vitro hair follicles, or tissue sheets containing fully developed human hair follicles, or integrate biodegradable material scaffolds for aiding the generation of asymmetry in the structure of said tissue sheets or in the shafts of said hair follicles.

The lack of hypoimmunogenic bioengineered hair follicles and hair follicle containing sheets with defined position of hair shafts, result in the use of natural sources for cosmetic surgeries, such us autologous donated human hair samples.

Our invention describes a method for deriving hair follicles and sheets containing hairfollicles using autogenous AND allogeneic sources, and can be implemented in good manufacturing procedures pipelines and xeno free conditions. Furthermore, using as source biodegradable grids containing and carrying said hair follicles, facilitates the downstream surgical process by augmenting the hair follicle count used and handled per surgical step.

Nevertheless we must conduct our work as accurate and as precise as possible. This requires time and detailed analysis of the patients pathogenesis.

NON APPROVED STEMCELL THERAPIES

At HAIROID™️ we strictly campaign against the unethical and dangerous practice of non approved stemcell therapies and associated assays. Despite we produce patented bioengineered de novo human hairfollicles for transplantation and compound testing; we will implement, with the utmost scientific and technological rigor, procedures in absolute accordance with the respective governmental regulations. Here we will focus on EMA approvals. 

All testing offers to physicians from aside our firm are related to the identification of patients specific pathology, within the use of all available analysis tools on the market. Under no circumstances we purpose or perform any unproven or dangerous procedures to/on patients or participants in clinical trials or compassionate use experiments, nor will we communicate project details before reaching clinical trails PHASE I.